Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy

Journal of Rheumatology

Volumn 37, Issue 7, 2010, Pages 1405-1410

  Drouin, Julie ^a   Haraoui, Boulos ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Methotrexate; Prognosis; Rheumatoid arthritis; Systematic review

Indexed keywords

FOLIC ACID; METHOTREXATE; RHEUMATOID FACTOR;

ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE COURSE; FOLLOW UP; HUMAN; MONOTHERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT RESPONSE;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; METHOTREXATE; PREDICTIVE VALUE OF TESTS;

EID: 77954428742     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090838     Document Type: Article

References (27)

1. Hayden J, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144:427-37. (Pubitemid 46768164)
2. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol 1995;22:218-23.
3. Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
4. Hoekstra M, van Ede AE, Haagsma CJ, van de Laar MA, Huizinga TW, Kruijsen MW, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:423-6.
5. Smolen JS, van der Heijde DM, St. Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006;54:702-10.
6. Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998;37:1220-6. (Pubitemid 28526081)
7. Lie E, Heiberg MS, Nordvag BY, Rodevand E, Kaufmann C, Mikkelsen K, et al. Predictors of response to methotrexate treatment: Results from a longitudinal observationnal study of 876 patients with RA [abstract]. Ann Rheum Dis 2006;65 Suppl II:342.
8. Weinblatt ME, Keystone EC, Cohen MD, Freundlich B, Li J, Chon Y, et al. Predictors of poor radiographic response in rheumatoid arthritis subjects treated with methotrexate: preliminary analysis from ERA and TEMPO studies [abstract]. Arthritis Rheum 2006;54 Suppl:S181.
9. Van der Heijde DM, Landewe R, Sharp JT, Bathon J, Patra K, Spencer-Green GT. Baseline CRP concentrations predict radiographic progression in MTX-naive patients with recent-onset RA: Subanalysis of the PREMIER study [abstract]. Ann Rheum Dis 2005;64 Suppl III:436.
10. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35.
11. Hider SL, Buckley C, Silman AJ, Symmons DP, Bruce IN. Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis. J Rheumatol 2005;32:11-6. (Pubitemid 40092583)
12. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, FARR Study Group. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. Clin Exp Rheumatol 2006;24 Suppl 43:S-77-82.
13. Boers M, Kostense PJ, Verhoeven AC, van der Linden S, COBRA Trial Group, Combinatietherapie Bij Reumatoide Artritis. Inflammation and damage in an individual joint predict further damage in that joint in patients with early rheumatoid arthritis. Arthritis Rheum 2001;44:2242-6.
14. Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou J, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001;44:1736-43.
15. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.
16. Garnero P, Landewe R, Boers M, Verhoeven A, van der Linden S, Christgau S, et al. Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study. Arthritis Rheum 2002;46:2847-56.
17. Kaltenhauser S, Wagner U, Schuster E, Wassmuth R, Arnold S, Seidel W, et al. Immunogenetic markers and seropositivity predict radiological progression in early rheumatoid arthritis independent of disease activity. J Rheumatol 2001;28:735-44.
18. Landewe R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, et al. Markers for type ii collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis. Arthritis Rheum 2004;50:1390-9.
19. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
20. Lindqvist E, Jonsson K, Saxne T, Eberhardt K. Course of radiographic damage over 10 years in a cohort with early rheumatoid arthritis. Ann Rheum Dis 2003;62:611-6.
21. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007;46:342-9.
22. Menninger H, Herborn G, Sander O, Blechschmidt J, Rau R. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. Br J Rheumatol 1998;37:1060-8. (Pubitemid 28492925)
23. Sanmarti R, Gomez A, Ercilla G, Gratacos J, Larrosa M, Suris X, et al. Radiological progression in early rheumatoid arthritis after DMARDs: a one-year follow-up study in a clinical setting. Rheumatology 2003;42:1044-9.
24. Sanmarti R, Gomez-Centeno A, Ercilla G, Larrosa M, Vinas O, Vazquez I, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. Clin Rheumatol 2007;26:1111-8.
25. van der Heijde DM, van Riel PL, van Leeuwen MA, van 't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
26. Vittecoq O, Pouplin S, Krzanowska K, Jouen-Beades F, Menard JF, Gayet A, et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology 2003;42:939-46.
27. Welsing PM, Landewé RB, van Riel PL, Boers M, van Gestel AM, van der Linden S, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004;50:2082-93.